克律克斯生物制药:Keryx Biopharmaceuticals(KERX)

克律克斯生物制药公司Keryx Biopharmaceuticals Inc.(NASDAQ:KERX)创立于1997年,总部位于美国纽约,全职雇员184人,是一家生物制药公司,专注于肾脏疾病相关治疗药物的研发。

克律克斯生物制药:Keryx Biopharmaceuticals(KERX)

克律克斯生物制药Keryx Biopharmaceuticals(KERX)美股百科:

克律克斯生物制药公司专注于研发并商品化肾脏疾病相关药物,公司主要候选药物用于治疗末期肾脏病(ESRD,End Stage Renal Disease)所引起的高血磷症,现已完成III期临床试验。同时,该产品也可用于治疗非透析依赖性慢性肾脏病(CKD,chronic kidney disease)所引发的缺铁性贫血,目前也已进入II期临床试验阶段。

2014年9月,美国FDA批准了公司的第一款产品——Auryxia™柠檬酸铁片。

此外,Keryx Biopharmaceuticals Inc.与Japan Tobacco Inc. 和Torii Pharmaceutical Co.有许可协议,在日本开发Auryxia,并与Panion & BF Biotech, Inc. 结成战略联盟。

克律克斯生物制药Keryx Biopharmaceuticals(KERX)美股投资:

参考资料:

美股代码NASDAQ:KERX公司官网http://www.keryx.com
行情走势xueqiu.com/S/KERX美股百科www.mg21.com/KERX.html

机构评级:

2016-2-29FBR Capital升级从:大市一致到:跑赢大市
2016-2-26Raymond James升级从:大市一致到:跑赢大市
2016-2-26JP Morgan降级从:增持到:中性
2015-10-5Morgan Stanley升级从:跑输大市到:持有
2015-9-3Citigroup初评到:卖出
2015-8-10ROTH Capital降级从:买入到:中性

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen:

目前评论:1   其中:访客  0   博主  1

  1. avatar 美股之家

    2016年7月底,Zacks专业研报:

    Keryx Biopharma (KERX) uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases.

    Protein kinases play a key role in the way cells communicate. KERX met the Zacks Consensus Estimate of a loss of $0.22 when it last reported in late April. The key, though, was that the topline has seen sequential growth in each of the last four quarters.

    The March 2015 revenue was $1M, and followed by $3M, $4M, $6M and $7M in the most recent quarter. These are very small numbers, but the idea here is that there is good sequential growth. We expect to see more of the same as the consensus estimate for next quarter is $8M. Revenue growth of 200% is expected this year and another 136% is slated for next year.

    Earnings are set to improve significantly as well, and if that happens, the stock will continue to appreciate.